Q2 Earnings: Regeneron and Cigna Outperform Expectations
- August 03rd, 2023
- 208 views
Shares of Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) surged over 5% in pre-market trading following an impressive second quarter 2023 earnings report. The company exceeded expectations, reporting adjusted earnings per share (EPS) of $10.24 and revenues of $3.16 billion, surpassing the consensus estimates of $9.84 on revenues of $3.01 billion.
In pre-market, $REGN was trading at $778.10, reflecting a gain of $45.98 (+6.28%).
In a separate development, The Cigna Group (NYSE: CI) unveiled its Q2 2023 financial results, with adjusted EPS of $6.13 and revenues of $48.62 billion, outperforming the consensus estimate of $6.02 on revenue of $47.31 billion.
Looking ahead, the company provided an optimistic outlook for full-year 2023 adjusted EPS, targeting at least $24.70, surpassing the consensus projection of $24.69.
$CI was trading at $299.80 in pre-market, up $0.40 (+0.13%)
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)
Post Your Comments
Want To Find Some News?
Recent Posts
-
CSX, VinFast Auto, and Crown Castle's Earnings Preview
April 14th, 2024Earnings Spotlight: McCormick, TD SYNNEX, and GameStop Set to Report
March 23rd, 2024Upcoming Earnings: Adobe, Ulta Beauty, and Smartsheet Under the Lens
March 10th, 2024
Member Login